



Correction to: Ivosidenib in relapsed or refractory acute myeloid leukemia: a profile of its use in the USA

Emma H. McCafferty¹ · Katherine Ann Lyseng-Williamson¹ 

Published online: 10 June 2019
© Springer Nature 2019

Correction to:
Drugs & Therapy Perspectives (2019) 35:160–166
<https://doi.org/10.1007/s40267-019-00610-2>

The original article was originally published Online First without open access. After publication in volume 35, issue 4, pages 160–166, Agios Pharmaceuticals requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Agios Pharmaceuticals. The article is forthwith distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any non-commercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The original article has been corrected.

Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any

noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

The original article can be found online at <https://doi.org/10.1007/s40267-019-00610-2>.

✉ Katherine Ann Lyseng-Williamson
dtp@adis.com

¹ Springer, Private Bag 65901, Mairangi Bay, 0754 Auckland, New Zealand